Seth Harmon
Fortuna: 138 317 $ al 31/05/2026
Fortuna: 138 317 $ al 31/05/2026
Seth Harmon is currently Chief Financial & Accounting Officer at Viridian Therapeutics, Inc. since 2023.
Formerly, Mr. Harmon was Chief Financial Officer at BioNTech SE from 2020 to 2023 and Vice President-Finance at BioNTech US, Inc. from 2017 to 2020.
Mr. Harmon completed undergraduate studies at Bowdoin College and earned graduate degrees, including an MBA, from Northeastern University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/03/2026 | 7.850 ( 0,01 % ) | 138 317 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Director Financiero/CFO | 12/09/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
| BIONTECH SE | Director Financiero/CFO | 01/05/2023 |
| NEON THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2020 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Bowdoin College
Bowdoin College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNTech SE
BioNTech SE BiotechnologyHealth Technology Develops immunotherapies and mRNA-based vaccines to treat cancer & infectious diseases | Health Technology |
BioNTech US, Inc.
BioNTech US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immunotherapies for cancer | Health Technology |
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures monoclonal antibody products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.